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Background: HIV-1 infected patients frequently have osteolytic bone disease, which is caused by the dysregulation
of the bone remodeling system that involves the interaction between osteoblasts and osteoclasts, but the
relationship between osteolytic disease and HIV-1 infection remains unclear. In this study we tested whether HIV-1
infection of osteoclasts affects their differentiation.
Results: We prepared human osteoclasts from CD14+ monocytes and examined them for their susceptibility to
HIV-1. Furthermore, we investigated the effect of HIV-1 infection on osteoclast differentiation. CD14-derived
osteoclasts were shown to express CD4, CCR5, and CXCR4 each at the similar level to that shown with macrophages.
R5-tropic HIV-1 and X4-tropic HIV-1 were found to infect CD14-derived osteoclasts and replicate in them. Furthermore,
HIV-1 infection induced formation of larger osteoclastst, enhanced the expression of mRNAs for three osteoclast specific
marker molecules (tartrate-resistant acid phosphatase, cathepsin K, and the calcitonin receptor), and up-regulated
osteoclast bone resorption activity.
Conclusions: Our results suggest that osteoclasts serve as a novel target for HIV-1 infection, which may enhance the
osteoclast differentiation contributing to the development of osteolytic disease in HIV-1-infected patients.
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Over the past decades, the use of highly active antiviral
therapy (HAART) has succeeded in extending the life
span of the HIV-1-infected patients by dramatically re-
ducing mortality among the patients. However, the in-
creased average life span has given rise to long-term
complications of HIV-1 infection, resulting in cardiovas-
cular disease, hepatic toxicity, and metabolic disorder
[1,2]. Osteolytic bone disease has emerged as one of
these complications. Osteolytic bone disease, such as
osteoporosis or osteopenia, is characterized by reduction
of bone mineral density (BMD). One meta-analysis of
prevalence data on osteolytic disease demonstrated that
BMD reduction was observed in 67% of HIV-1-infected
patients [3]. Although the mechanisms underlying the* Correspondence: imoakat@ims.u-tokyo.ac.jp
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are largely unclear, multiple risk factors are believed to
contribute to development of the osteolytic bone dis-
order. To date, HAART has been shown to cause bone
metabolism alterations, leading to BMD reduction [3].
Also, there is clear evidence of reduced BMD in HAART-
naïve HIV-1-infected patients [4,5], revealing that HIV-1
infection itself contributes to the development of osteo-
lytic disease.
Bone metabolism is strictly regulated by the bone
metabolic turnover, which is referred to as bone remod-
eling. Bone remodeling consists of the opposing func-
tions of the two cell types, osteoblasts, which produce
new bone, and osteoclasts, which resorb old bone. The
RANK (Receptor activator of NF-κB)/RANKL (RANK
ligand) system dominantly regulates osteoclast forma-
tion. RANKL is mainly expressed on the cell surface of
osteoblasts and stromal cells, and binding of RANKL to
the receptor RANK that exists on the cell surface of osteo-
clast progenitor cells derived from the monocytic popula-
tion leads to osteoclast differentiation [6]. Osteoclasts areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Gohda et al. Retrovirology  (2015) 12:12 Page 2 of 10giant multi-nucleated cells that have the well-developed
actin cytoskeleton firmly attached to the bone surface. In
the bone of the patients with osteolytic disease, excess for-
mation and abnormal bone resorbing activity of osteo-
clasts are frequently observed [7]. Interestingly, a recent
study shows that HIV-1 transgenic rats undergo severe
BMD reduction similar to osteoporosis probably through
the enhancement of osteoclast formation [8]. However, it
remains unclear how HIV-1 infection alters osteoclast for-
mation and functions, resulting in BMD reduction in
HIV-1-infected patients.
In this study we attempted to test the hypothesis that
osteoclast differentiation be affected by infection of oste-
oclasts with HIV-1, since osteoclasts are differentiated
from the myeloid-linage progenitor cells, like HIV-1 sus-
ceptible monocytes and macrophages.
Results
CD14-derived osteoclasts are susceptible to HIV infection
in vitro
We characterized human osteoclasts generated by cultur-
ing with recombinant M-CSF plus RANKL the CD14+
monocytes purified from PBMCs [9]. After 6 to 7 days, a
large number of osteoclast-like multinucleated cells
(MNCs) (Figure 1A). Further incubation with M-CSF plus
RANKL induced formation of larger MNCs after 7 to
14 days. The MNCs expressed tartrate-resistant acid
phosphatase (TRAP), a specific osteoclast marker [10]
(Figure 1A). Furthermore, the MNCs were able to re-
sorb bone in the pit formation assay (Figure 1B). These
results indicate that the MNCs were osteoclasts. In con-
trast, CD14+ cells cultured with M-CSF alone expressed
a monocyte marker, CD14 at the same level as osteo-
clasts, and a macrophage specific marker, CD71 at a
higher level than osteoclasts (Figure 1C), but not form-
ing any TRAP-positive MNCs (Figure 1A).
We examined expression of CD4, CXCR4, and CCR5,
receptors for HIV-1 infection, in CD14-derived osteo-
clasts and macrophages. Flow cytometry analysis showed
that CD14-derived osteoclasts expressed all of the recep-
tors on their cell surface, each at the similar level to that
in the macrophages (Figure 1C).
We then exposed CD14-derived osteoclasts or macro-
phages to a CCR5-tropic (R5) HIV-1 strain, JR-FL or a
CXCR4-tropic (X4) HIV-1 strain, NL4-3, in order to
examine whether or not human osteoclasts are infected by
HIV-1. The cells were immunostained with anti-HIV-1
p24 and anti-TRAP antibodies, 40 hours after the infec-
tion. In both cases, some macrophages and TRAP+-MNCs
were found positive with p24 staining (Figure 2A). CD14-
derived osteoclasts were infected by JR-FL and NL4-3 as
efficiently as the macrophages, though JR-FL infected both
CD14-derived macrophages and osteoclasts more effi-
ciently than NL4-3 (Figure 2B). The treatment of the cellswith tenofovir (TFV), a reverse-transcriptase inhibitor,
prevented JR-FL and NL4-3 infection of CD14-derived
macrophages and osteoclasts in a dose-dependent manner
(Figure 2A,C).
Furthermore, the levels of p24 in the supernatants of
osteoclast cultures rised in a time-dependent manner, al-
though the p24 levels in CD14-derived osteoclasts were
lower then those in macrophages (Figure 3A). The rises
of the p24 levels were suppressed by TFV treatment
(Figure 3B), and the supernatants had infectivity
(Figure 3C), indicating that JR-FL and NL4-3 replicates
in CD14-derived macrophages and osteoclasts. Taken
together, these data (Figures 2 and 3) indicate that
HIV-1 can infect CD14-derived osteoclasts and repli-
cate in them.
HIV-1 infection enhances osteoclast differentiation
To elucidate possible link between HIV-1 infection and
osteolytic disease, we tested whether HIV-1 infection
has any effects on osteoclast differentiation. Microscopic
analyses of the TRAP-stained cells revealed that MNCs
incubated with JR-FL were significantly increased in size
and number of nuclei per cell, in comparison with nor-
mal CD14-derived osteoclasts (Figure 4A). In contrast,
MNCs treated with TFV or incubated with aldrithiol-2
(AT-2)-inactivated JR-FL were similar to normal CD14-
derived osteoclasts.
We further analyzed mRNA expression of specific osteo-
clast markers, such as acid phosphatase 5 (ACP5) /TRAP,
cathepsin K (CTSK), and the calcitonin receptor
(CALCR) [11], in the cells infected with different doses
of JR-FL or AT-2-inactivated JR-FL (Figure 4B). In the
macrophages, these marker expression levels were very
low and there was no significant difference in their ex-
pressions between the uninfected and infected cells. In
contrast, all of the markers were expressed at high levels
in the uninfected CD14-derived osteoclasts and further
up-regulated by the viral infection in a dose-dependent
manner. However, infection with AT-2-inactivated JR-
FL did not significantly affect the maker expressions in
CD14-derived osteoclasts. TFV treatment suppressed
the enhancement of the maker expressions by JR-FL in-
fection in a dose-dependent manner without any effect
on the maker expression levels in the uninfected CD14-
derived osteoclasts (Figure 4C).
On the other hand, NL4-3 infection also increased in
size and number of nuclei, and enhanced the osteoclast
marker expessions, although its effects were less marked as
compared with JR-FL infection (Figures 4A,B and 5A,B).
Infection with AT-2-inactivated NL4-3 did not affect the
cell size and the marker expressions (Figure 5A,B). In
addition, TFV treatment inhibited the increase in size and
number of nuclei per cell and the enhancement of the
marker expression levels (Figure 5A,C).










Figure 1 In vitro osteoclast formation and expressions of the receptors. (A) CD14+ monocytes isolated from the PBMCs from healthy
donors were cultured for 7 days with M-CSF plus RANKL, or M-CSF alone to generate osteoclasts and macrophages. The induced osteoclasts
(the left photo) and macrophages (the right photo) were fixed and stained for TRAP. TRAP-positive cells appeared as red cells. Scale bar, 100 μm.
(B) CD14+ monocytes isolated from the PBMCs from healthy donors were cultured for 10 days with M-CSF plus RANKL, or M-CSF alone on
calcium phosphate-coated wells. After removing the cells, formed pits (white area) were observed by microscopy. Scale bar, 300 μm. (C) Osteoclasts
(OC) and macrophages (Mph) induced by 7 days culture of CD14+ cells with M-CSF plus RANKL or M-CSF alone were harvested and immunostained
with anti-CD4, CXCR4, CCR5, CD14, and CD71 antibodies and analyzed by FACS. Pink histograms represent the cells stained with antibodies against
each receptor. Green histograms represent the cells stained with each isotype-matched control antibody.
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the effect of HIV-1 infection on osteoclast bone resorption
activity. Microscopic images showed that pit areas pro-
duced by JR-FL or NL4-3-infected osteoclasts were larger
than those by the uninfected osteoclasts (Figure 6A). Pit
formation was enhanced by JR-FL infection and, to a lesser
extent, by NL4-3 (Figure 6A,B). Furthermore, TFV treat-
ment suppressed an increase in pit formation by viral in-
fection (Figure 6A,C). Accordingly, these results strongly
suggest that HIV-1 infection enhances osteoclast differen-
tiation and bone resoption activity.Discussion
We here show that CD14-derived osteoclasts can be also
infected with HIV-1 like other myeloid-linage cell types,
such as monocytes and macrophages. In addition, HIV-1
can also replicate in CD14-derived osteoclasts. Our data
showed that CD14-derived osteoclasts were susceptible
to both R5 and X4 tropic HIV-1. R5 HIV-1 (JR-FL) in-
fects CD14-derived osteoclasts and macrophages and
replicates more efficiently than X4 HIV-1 (NL4-3). It is
unknown why there is a difference in efficiency of infec-
























































































































Figure 2 HIV-1 infection of osteoclasts. (A) The induced osteoclasts (OC) and macrophages (Mph) were incubated for 6 hours with R5-tropic
JR-FL (2.5 × 105 IFU/ml) or X4-tropic NL4-3 (2.5 × 105 IFU/ml) in the absence or presence of 4 μg/ml TFV. Forty hours after infection, the cells were
fixed and stained with anti-HIV-1 p24 and anti-TRAP antibodies. The green and red signals show expressions of HIV-1 p24 and TRAP, respectively.
The blue signals show nucleus stained with Hoechst 33258. Scale bar, 100 μm. (B) The induced osteoclasts and macrophages were infected with
JR-FL or NL4-3 at the indicated doses. Forty hours after infection, the cells were stained with anti-HIV-1 p24 and anti-TRAP antibodies. The number
of p24-positive and negative cells was counted. The bars show the ratio of p24-positive cells to total cells on a logarithmic scale. (C) The induced
osteoclasts and macrophages were infected with JR-FL (2.5 × 105 IFU/ml) or NL4-3 (2.5 × 105 IFU/ml) in the presence of TFV at the indicated
concentrations. Forty hours after infection, the cells were stained with anti-HIV-1 p24 and anti-TRAP antibodies. The number of p24-positive and
negative cells was counted. ND means not detected.
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that of R5 HIV-1 [12]. However, both viruses can infect
CD14-derived osteoclasts and macrophages with similar
efficiency (Figure 2). On the other hand, HIV-1 less effi-
ciently replicates in CD14-derived osteoclasts compared
to macrophages, even though HIV-1 infects both the cell
types to the same extent. Why the infection andreplication rates are different remains unclear. One pos-
sible reason is that osteoclasts might produce a fewer
viral particles than macrophages due to the impairment
of some step after proviral integration in the HIV-1 life
cycle. The further study is needed.
“HIV-1 reservoirs” have recently become a major obs-
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Figure 3 HIV-1 replication in osteoclasts. (A) The induced osteoclasts (circles) and macrophages (triangles) were incubated for 6 hours with a
JR-FL or NL4-3 strain at the indicated doses and washed to remove free virus. Viral p24 concentration in the cell culture supernatants collected
on day 3, 6, and 9 was monitored by ELISA. (*p < 0.05, **p < 0.01 by t test between day 3 and each day in each cell type) (B) The induced osteoclasts
(black bars) and macropharges (white bars) were infected with JR-FL (2.5 × 105 IFU/ml) or NL4-3 (2.5 × 105 IFU/ml) in the presence of TFV at the
indicated concentrations. Viral p24 concentrations in the cell culture supernatants on day 6 (JR-FL) or day 9 (NL4-3) were measured by ELISA. (*p < 0.05,
**p < 0.01 by t test between None and each TFV sample) ND means not detected. (C) The supernatants from CD14-derived macrophages and
osteoclasts infected with JR-FL (2.5 × 105 IFU/ml) or NL4-3 (2.5 × 105 IFU/ml) in the absence or presence of 4 μg/ml TFV were collected on day 9 after
infection (shown in Figure 3C). MAGIC5 cells, susceptible to both R5 and X4 HIV-1, were incubated for 6 hours with each supernatant. Three days after
infection, the cells were fixed and stained with anti-p24 antibody and Hoechst 33258. The supernatant from the uninfected macrophages was used as
a control (Cont.). Scale bar, 100 μm.
Gohda et al. Retrovirology  (2015) 12:12 Page 5 of 10the antiviral treatment and the host immune response,
persisting for a long period of time. Several candidates
for HIV-1 reservoirs, including resting CD4+ T cells,
monocytes/macrophages, astrocytes, and hematopoietic
progenitor cells, have been suggested so far [13]. Al-
though we do not have any evidence that humanosteoclasts can be infected with HIV-1 in vivo, our re-
sults suggest that osteoclasts may act as an HIV-1 reser-
voir. The limited viral replication in osteoclasts may
allow the cells to escape the host immune response.
Osteoclasts are crucial for keeping a normal state of
bone homeostasis. Recent studies reported that several
None TFV
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Figure 4 Effect of R5 HIV-1 infection on osteoclast differentiation. (A) CD14+ monocytes were cultured for 6 days with M-CSF plus RANKL.
The cells were infected with JR-FL (2.5 × 105 IFU/ml) in the absence or presence of 4 μg/ml TFV or with AT-2-inactivated JR-FL (2.5 × 105 IFU/ml).
Five days after infection, the cells were fixed and stained for TRAP. Scale bar, 300 μm. (B) CD14+ monocytes were cultured for 6 days with M-CSF
plus RANKL (OC) or M-CSF alone (Mph). The cells were infected with JR-FL or with AT-2-inactivated JR-FL at the indicated doses. Five days after
infection, total RNA was prepared and the expressions of the osteoclast markers, such as ACP5/TRAP, CTSK, and CALCR, were analyzed by quantitative
real-time RT-PCR. (C) CD14+ monocytes were cultured for 6 days with M-CSF plus RANKL (OC) or M-CSF alone (Mph). The osteoclasts were infected
with JR-FL in the presence of TFV at the indicated doses. Five days after infection, the expressions of ACP5/TRAP, CTSK, and CALCR were analyzed by
quantitative real-time RT-PCR. (B, C) The relative mRNA expression level of each marker is shown as fold induction in comparison to the expression in
the uninfected macrophages. The data were standardized by the level of β-actin expression in each sample. (*p < 0.05, **p < 0.01 by t test).
Gohda et al. Retrovirology  (2015) 12:12 Page 6 of 10markers of bone resorption are markedly increased in
HIV-1-infected patients in comparison with healthy indi-
viduals [14], suggesting that osteoclasts are involved in
the development of osteolytic disorder in the HIV-1 pa-
tients. However, osteoclast formation and functions inthe bone of HIV-1-infected patients await further inves-
tigation. Our data showed that CD14-derived osteoclasts
became larger in size with more nuclei in a single cell
than normal CD14-derived osteoclasts after incubation
with HIV-1. The formation of larger osteoclasts is
None TFV
AT-2-treated 

























































































































































Figure 5 Effect of X4 HIV-1 infection on osteoclast differentiation. (A) CD14+ monocytes were cultured for 6 days with M-CSF plus RANKL.
The cells were infected with NL4-3 (2.5 × 105 IFU/ml) in the absence or presence of 4 μg/ml TFV or with AT-2-inactivated NL4-3 (2.5 × 105 IFU/
ml). Five days after infection, the cells were fixed and stained for TRAP. Scale bar, 300 μm. (B) CD14+ monocytes were cultured for 6 days with M-CSF
plus RANKL (OC) or M-CSF alone (Mph). The cells were infected with NL4-3 or with AT-2-inactivated NL4-3 at the indicated doses. Five days after
infection, total RNA was prepared and the expressions of the osteoclast markers, such as ACP5/TRAP, CTSK, and CALCR, were analyzed by quantitative
real-time RT-PCR. (C) CD14+ monocytes were cultured for 6 days with M-CSF plus RANKL (OC) or M-CSF alone (Mph). The osteoclasts were infected
with NL4-3 in the presence of TFV at the indicated doses. Five days after infection, the expressions of ACP5/TRAP, CTSK, and CALCR were analyzed by
quantitative real-time RT-PCR. (B, C) The relative mRNA expression level of each marker is shown as fold induction in comparison to the expression in
the uninfected macrophages. The data were standardized by the level of β-actin expression in each sample. (*p < 0.05 by t test).
Gohda et al. Retrovirology  (2015) 12:12 Page 7 of 10unlikely to have resulted from syncytium formation in-
duced by HIV-1 infection, because expressions of several
osteoclast specific markers, which are closely related to
the bone-resorbing activity of osteoclasts [10,15,16],
were elevated in CD14-derived osteoclasts incubated
with HIV-1. In fact, a pit assay showed that HIV-1infection enhanced bone resorption activity of CD14-
derived osteoclasts. These results strongly suggest that
HIV-1 infection enhances osteoclast differentiation and
functions. TFV treatment and AT-2-treated inactivation
of the HIV-1 replication activity inhibited the enhance-
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Figure 6 Effect of HIV-1 infection on bone resorption activity of osteoclasts. (A) CD14+ monocytes isolated from the PBMCs from healthy
donors were cultured for 6 days with M-CSF plus RANKL, or M-CSF alone on calcium phosphate-coated wells. Then, the cells were infected with
JR-FL (2.5 × 105 IFU/ml) or NL4-3 (2.5 × 105 IFU/ml) in the absence or presence of 4 μg/ml TFV. Five days after infection, formed pits (white area)
were observed by microscopy. Scale bar, 300 μm. (B) The induced osteoclasts (for 6 days culture with RANKL plus M-CSF) were infected with
JR-FL or with NL4-3 at the indicated doses. Five days after infection, the pit areas were measured. (C) The induced osteoclasts (for 6 day culture
with RANKL plus M-CSF) were infected with JR-FL (2.5 x 105 IFU/ml) or with NL4-3 (2.5 × 105 IFU/ml) in the presence of TFV at the indicated
concentrations. Five days after infection, the pit areas were measured. (*p < 0.05 by t test).
Gohda et al. Retrovirology  (2015) 12:12 Page 8 of 10expressions in CD14-derived osteoclasts. In addition, JR-FL
infection facilitated osteoclast differentiation more than
NL4-3 infection, which is less effective to osteoclasts than
JR-FL infection. These indicate that HIV-1 replication
might be required for the enhancement of osteoclast differ-
entiation. Taken together, the enhancement of osteoclast
differentiation by HIV-1 infection is likely to contribute to
BMD reduction observed in HIV-1-infected patients.Although how HIV-1 infection facilitates osteoclast dif-
ferentiation remains unclear, direct and indirect mechanism
may be involved. A recent study shows that recombinant
Tat protein enhances osteoclast differentiation induced by
RANKL plus M-CSF, suggesting that Tat protein secreted
from the infected cells may affect osteoclast formation
[17]. In addition to the viral components, inflammatory
cytokines produced by HIV-1 infection may enhance
Gohda et al. Retrovirology  (2015) 12:12 Page 9 of 10osteoclastogenesis. Formation of osteoclasts and their
bone-resorbing activity are enhanced by various kinds of in-
flammatory cytokines, such as IL-1, IL-6, and TNF-α [18].
Further elucidation of the molecular mechanisms under-
lying the HIV-1 infection-mediated enhancement of osteo-
clastogenesis is needed.
Conclusions
We have shown the susceptibility of CD14-derived oste-
oclasts to HIV-1 and the enhancement of osteoclast dif-
ferentiation and function by HIV-1 infection. Thus,
these suggest that HIV-1 infection of osteoclasts is one
of the causative factors for the development of osteolytic
bone disease, such as osteoporosis or osteopenia, in
HIV-1-infected patients.
Methods
Cell culture and preparation of osteoclasts and
macrophages
HEK293FT and MAGIC5 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS). For prepar-
ation of osteoclasts and macrophages, CD14+ monocytes
were isolated with a purity percentage >95% by using the
MACS CD14 Microbeads (Miltenyi Biotech), from periph-
eral blood mononuclear cells (PBMCs) prepared from two
different healthy male donors by Ficoll-Paque (GE Helth-
care) density gradient centrifugation. Informed consent
for all procedures was obtained from both donors. Cells
were cultured for 7 days in Osteoclast Precursor Basal
Medium (Lonza) containing 10% FBS with recombinant
human macrophage colony-stimulating factor (M-CSF)
(33 ng/ml; Peprotech) plus human RANKL (50 ng/ml;
Peprotech) or with M-CSF alone. This study was approved
by the Ethics Committe of the Institute of Medical
Science, The University of Tokyo (Reference number: 24-
68-0304).
Pit formation assay
CD14+ monocytes were cultured for 10 days with M-
CSF or with M-CSF plus RANKL in Bone Resorption
Assay kit 24 (PG Research). After removing cells with
5% NaClO, pit formation was observed with a micro-
scope and photographed. The pit areas were measured
with ImageJ [19].
Tartrate-resistant acid phosphatase (TRAP) staining and
immuno-staining of cells and flow cytometry
TRAP staining was carried out with TRAP-staining kit
(Primary Cell Co.). For immunostaining, cells were fixed
with 4% paraformaldehyde. Then, cells were permeabilized
and blocked with PBS containing 2% bovine serum albu-
min (BSA) and 0.01% Tween 20, and incubated with anti-
HIV p24 antibody (clone Kal-1; Dakocytomation) andanti-TRAP antibody (Santa Cruz). After being washed,
cells were further incubated with Alexa Fluor 488 anti-
mouse IgG (Molecular Probes), Alexa Fluor 546 anti-
rabbit IgG (Molecular Probes), and Hoechst33258
(Molecular Probes). The images of fluorescence were
acquired by fluorescent microscopy using a BZ-8000
(Keyence). For flow cytometry, cells were harvested
with 10 mM EDTA/PBS. After preincubation with a
human Fc receptor blocking reagent (MBL), cells were
stained with the corresponding antibodies. Fluorescence
was analyzed with a FACSCalibur (Becton Dickinson).
The following antibodies were used for staining: fluores-
cein isothiocyanate (FITC) -labeled anti CD4, CD184/
CXCR4, CD195/CCR5, CD14, and CD71. In addition, the
following isotype controls were used as negative controls
for staining for each receptor: FITC-labeled mouse IgG1
for CD4, FITC-labeled rat IgG1 for CXCR4, and FITC-
labeled rat IgG2a for CCR5. All of the antibodies except
for CD14 and CD71 (Miltenyi Biotech) were obtained
from MBL.
Viral preparations and infection
HEK293FT cells were transfected with a JR-FL [20] or
NL4-3 [21] vector using Lipofectamine 2000 (Invitro-
gen). Two days after transfection, the supernatants were
collected and centrifuged to remove the cells. Titration
of viral solution was performed by HIV-1 p24 quantifica-
tion using the HIV-1 p24 ELISA kit (ZeptoMetrix). In-
fectious units (IFU) of each virus stock were determined
by p24 immuno-staining of infected MAGIC5 cells, sus-
ceptible to both R5 and X4 tropic HIV-1 [22]. Inacti-
vated viruses were prepared by incubating the viral
supernatants with 500 mM aldrithiol-2 (Sigma) at 4°C
overnight [23]. For infection of macrophages and osteo-
clasts, cells were incubated for 6 hours with JR-FL or
NL4-3, washed three times with OPBM, and further cul-
tured for the indicated times. Tenofovir (Selleckchem) was
added at the indicate concentrations 30 min before infec-
tion and added again after washing with OPBM. After de-
tection of infected cells by p24 immuno-staining, the
number of infected macrophages and osteoclasts in total
1000 to 3000 cells was counted to determine the infectious
rates. The levels of p24 in the supernatants were measured
by HIV-1 p24 ELISA (XpressBio). For infection of
MAGIC5 cells, cells were incubated for 6 hours with the
supernatants in 6 or 9 days cultures of the IR-FL- or NL4-
3-infected macrophages and osteoclasts, washed three
times with fresh medium, and further cultured for 3 days.
Quantitative real-time PCR
Total RNA was reverse transcribed with Primescript RT
reagent kit (TAKARA) using oligo dT primers. Real-
time RT-PCR analysis was performed using a TP870
thermal cycler (TAKARA) and SYBR Premix Ex Taq II
Gohda et al. Retrovirology  (2015) 12:12 Page 10 of 10(TAKARA). The level of β-actin expression in each sample
was used to standardize the data. The following primer









The P values were calculated with the Student’s t test
with Microsoft Excel software, with two-tailed distribu-
tion and two-sample unequal variance parameters.
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